BioSpace News Archive

Successful listing on TSXV advances Small Pharma’s bold vision to revolutionize the treatment of patients with mental health conditions through psychedelic-assisted therapies

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, today reported financial results for the quarter ended March 31, 2021, and provided a business update.

European Biotech Acquisition Corp. announced that, commencing May 6, 2021, holders of the units sold in the Company’s initial public offering of 12,000,000 units, completed on March 18, 2021, and the subsequent sale of an additional 754,784 units upon partial-exercise of the underwriters’ over-allotment option, completed on May 3, 2021, may elect to separately trade the shares of Class A ordinary shares and warrants included in the units.

Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Newron Pharmaceuticals S.p.A. (“Newron”) received a Paragraph IV Notice Letter (“Notice Letter”) from Aurobindo Pharma Limited,

EDELWEISS 3trial of Yselty® expected to report topline data as plannedin Q4:21

Posters highlight ensifentrine’s safety profile and its potential to improve lung function and quality of life irrespective of COPD severity

During Q1, the global installed base for IRRAS products increased; the total number of IRRAflow systems increased from 73 to 84 and Hummingbird systems grew from 5 to 9.

Innate Pharma SA, announced that the Company will hold a conference call on Thursday, May 11, 2021 at 3 p.m. CEST / 9 a.m. ET, to give an update on business progress during the first quarter of 2021.

Press Release Nicox’s Licensee Bausch + Lomb Launches VYZULTA®(latanoprostene bunod ophthalmic solution), 0.024%in Taiwan and Receives Approval in Qatar